Boston Therapeutics

1750 Elm Street, Suite 103
Manchester, NH 03104

Phone: (603) 935-9799
Fax: (603) 685-4784

Recent News Releases

Boston Therapeutics secures $1 Million financing for the first phase Multi-Centre International Ph II-III Trial

Boston Therapeutics, Inc. and its Asian partner Advance Pharmaceutical Company Limited, Hong Kong, announced today the fully financed new trial plans to support the safety and efficacy of BTI320,...Read more

Boston Therapeutics Business Update

On February 1, 2017 Boston Therapeutics, Inc., headquartered in Lawrence MA, disclosed its restructured operations activity in a two part session covering the last five months as well as a look...Read more

Boston Therapeutics, Inc. :BTHE-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016

Categories: Yahoo Finance Get free summary analysis Boston Therapeutics, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following...Read more

Boston Therapeutics Announces Innovation Grant

Boston Therapeutics, Inc. - Today Boston Therapeutics and Advance Pharmaceutical Co., Ltd., which holds a license for the Company's products in Asia, are announcing another advancement in the...Read more

Boston Therapeutics, Inc. (BTHE-OTC)

Boston Therapeutics, Inc. (“the Company”) addresses the diabetes and inflammatory disease markets using complex carbohydrate chemistry (CCC) technology. The Company’s portfolio includes two development-stage pharmaceutical candidates as well as a marketed over-the-counter (OTC) dietary supplement. The OTC product, SugarDown®, is a chewable tablet designed to support healthy blood sugar levels. It is available and generating revenue in the U.S. and overseas markets. The lead pharmaceutical candidate, BTI-320, is a Phase II, non-systemic, non-toxic, carbohydrate-based tablet being evaluated as a therapy for Type 2 diabetes in patients currently taking metformin. The compound inhibits enzymes that release glucose from complex carbohydrates in foods during digestion—reducing the amount of glucose released from digested complex carbohydrates. Boston Therapeutics’ second pipeline candidate (currently in preclinical development) is Ipoxyn (and a veterinary analog of Ipoxyn, called OxyFex), which is a carbohydrate-based intravenous solution in development to treat hypoxic conditions caused by a lack of oxygen to living tissue, such as lower-limb ischemia stemming from severe diabetes. The Ipoxyn molecule, which is 5,000 times smaller than a red blood cell (RBC), works by picking up oxygen in the lungs and offloading it to tissue that has been oxygen-deprived. The Company is positioned to benefit from two simultaneous paths to market—OTC and pharmaceutical drug development.

* The Corporate Snapshot was last updated on August 22, 2014.

Latest Research

Boston Therapeutics Quarterly Update Cover

Quarterly Update